- Part 1 Principles of international endocrine practice
- Part 2 Pituitary and hypothalamic diseases
- Part 3 The thyroid
- Part 4 Parathyroid, calcium, and bone metabolism
- Part 5 The adrenal gland and endocrine hypertension
- Part 6 Neuroendocrine tumours and genetic disorders
- Part 7 Growth and development during childhood
- 7.1 Normal growth and sexual development
- 7.2 Growth and sexual disorders in childhood
- 7.2.1 Hypoglycaemia: assessment and management
- 7.2.2 Differential diagnosis of short stature and poor growth velocity
- 7.2.3 Genetic defects of the human somatotropic axis
- 7.2.4 Investigation of the slowly growing child
- 7.2.5 Growth hormone therapy for the growth-hormone deficient child
- 7.2.6 Growth-promoting agents for nongrowth hormone-deficient short children
- 7.2.7 Syndromic growth disorders
- 7.2.8 Tall stature
- 7.2.9 Delayed puberty and hypogonadism
- 7.2.10 Premature sexual maturation
- 7.3 Congenital adrenal hyperplasia in children
- 7.4 Late effects of cancer treatment
- 7.5 Transition in endocrinology
- Part 8 Female endocrinology and pregnancy
- Part 9 Male hypogonadism and infertility
- Part 10 Endocrinology of ageing and systemic disease
- Part 11 Endocrinology of cancer
- Part 12 Obesity, lipids, and metabolic disorders
- Part 13 Diabetes mellitus
Growth-promoting agents for nongrowth hormone-deficient short children
- Chapter:
- Growth-promoting agents for nongrowth hormone-deficient short children
- Author(s):
Pierre Chatelain
- DOI:
- 10.1093/med/9780199235292.003.7077
Growth-promoting agents refer to compounds, existing naturally or otherwise, which, when given to a short child as a medication, will accelerate growth velocity (GV), bringing the child’s height closer to or within normal range. The first objective, normalizing height during the growth phase, may not normalize adult height, which is the second objective. The ideal growth-promoting agent should normalize both. The mechanism behind these two objectives is not fully understood. It seems that when the growth plate cartilage chondrocytes multiply, they also differentiate then stop multiplying. The balance between multiplication and differentiation of growth plate chondrocytes is key to normalizing final height.
Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.
Please subscribe or login to access full text content.
If you have purchased a print title that contains an access token, please see the token for information about how to register your code.
For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.
- Part 1 Principles of international endocrine practice
- Part 2 Pituitary and hypothalamic diseases
- Part 3 The thyroid
- Part 4 Parathyroid, calcium, and bone metabolism
- Part 5 The adrenal gland and endocrine hypertension
- Part 6 Neuroendocrine tumours and genetic disorders
- Part 7 Growth and development during childhood
- 7.1 Normal growth and sexual development
- 7.2 Growth and sexual disorders in childhood
- 7.2.1 Hypoglycaemia: assessment and management
- 7.2.2 Differential diagnosis of short stature and poor growth velocity
- 7.2.3 Genetic defects of the human somatotropic axis
- 7.2.4 Investigation of the slowly growing child
- 7.2.5 Growth hormone therapy for the growth-hormone deficient child
- 7.2.6 Growth-promoting agents for nongrowth hormone-deficient short children
- 7.2.7 Syndromic growth disorders
- 7.2.8 Tall stature
- 7.2.9 Delayed puberty and hypogonadism
- 7.2.10 Premature sexual maturation
- 7.3 Congenital adrenal hyperplasia in children
- 7.4 Late effects of cancer treatment
- 7.5 Transition in endocrinology
- Part 8 Female endocrinology and pregnancy
- Part 9 Male hypogonadism and infertility
- Part 10 Endocrinology of ageing and systemic disease
- Part 11 Endocrinology of cancer
- Part 12 Obesity, lipids, and metabolic disorders
- Part 13 Diabetes mellitus